A previously published in‐house CISH protocol using a commercial digoxigenin (DIG)‐labeled
CCNE1 DNA probe (Empire Genomics, Buffalo, NY, USA) was used.
15 Deparaffinized 4‐μm tissue microarray sections were pretreated with proteinase K (3 min) and citrate‐based antigen retrieval buffer at 80°C (1 h) followed by pepsin (45 sec), and then dehydrated and air‐dried. Hybridization with the DIG‐labeled
CCNE1 probe was performed at 37°C for 16 to 18 hours in
HybEZ II (Advanced Cell Diagnostics, Minneapolis, MN, USA). A levamisole solution was used (15 min) to remove endogenous alkaline phosphatase activity, followed by a blocking solution (30 min) of 10% normal sheep serum, 2% bovine serum albumin, and 0.05% Tween‐20. An
alkaline phosphatase‐conjugated sheep anti‐DIG antibody (dilution 1:800; Roche, Basel, Switzerland) was incubated for 2 h. An alkaline phosphatase substrate was applied, and the reaction was stopped with 50 mM Tris, 150 mM NaCl, and 10 mM KCl buffer when slides reached the desired intensity of staining. Counterstaining was performed with hematoxylin.
Kang E., Weir A., Meagher N.S., Farrington K., Nelson G.S., Ghatage P., Lee C., Riggan M.J., Bolithon A., Popovic G., Leung B., Tang K., Lambie N., Millstein J., Alsop J., Anglesio M.S., Ataseven B., Barlow E., Beckmann M.W., Berger J., Bisinotto C., Bösmüller H., Boros J., Brand A.H., Brooks‐Wilson A., Brucker S.Y., Carney M.E., Casablanca Y., Cazorla‐Jiménez A., Cohen P.A., Conrads T.P., Cook L.S., Coulson P., Courtney‐Brooks M., Cramer D.W., Crowe P., Cunningham J.M., Cybulski C., Darcy K.M., El‐Bahrawy M.A., Elishaev E., Erber R., Farrell R., Fereday S., Fischer A., García M.J., Gayther S.A., Gentry‐Maharaj A., Gilks C.B., Grube M., Harnett P.R., Harrington S.P., Harter P., Hartmann A., Hecht J.L., Heikaus S., Hein A., Heitz F., Hendley J., Hernandez B.Y., Polo S.H., Heublein S., Hirasawa A., Høgdall E., Høgdall C.K., Horlings H.M., Huntsman D.G., Huzarski T., Jewell A., Jimenez‐Linan M., Jones M.E., Kaufmann S.H., Kennedy C.J., Khabele D., Kommoss F.K., Kruitwagen R.F., Lambrechts D., Le N.D., Lener M., Lester J., Leung Y., Linder A., Loverix L., Lubiński J., Madan R., Maxwell G.L., Modugno F., Neuhausen S.L., Olawaiye A., Olbrecht S., Orsulic S., Palacios J., Pearce C.L., Pike M.C., Quinn C.M., Mohan G.R., Rodríguez‐Antona C., Ruebner M., Ryan A., Salfinger S.G., Sasamoto N., Schildkraut J.M., Schoemaker M.J., Shah M., Sharma R., Shvetsov Y.B., Singh N., Sonke G.S., Steele L., Stewart C.J., Sundfeldt K., Swerdlow A.J., Talhouk A., Tan A., Taylor S.E., Terry K.L., Tołoczko A., Traficante N., Van de Vijver K.K., van der Aa M.A., Van Gorp T., Van Nieuwenhuysen E., van‐Wagensveld L., Vergote I., Vierkant R.A., Wang C., Wilkens L.R., Winham S.J., Wu A.H., Benitez J., Berchuck A., Candido dos Reis F.J., DeFazio A., Fasching P.A., Goode E.L., Goodman M.T., Gronwald J., Karlan B.Y., Kommoss S., Menon U., Sinn H., Staebler A., Brenton J.D., Bowtell D.D., Pharoah P.D., Ramus S.J, & Köbel M. (2022). CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. Cancer, 129(5), 697-713.